The Outcomes of Allogenic Bone Marrow Transplantation for BThalassemia Major Patients: Single-Centre Experience
International Journal of Research in Oncology · 2023
DOI: 10.33425/2833-0390.1014 ↗Kurz gefasst
Fachartikel in der Zeitschrift International Journal of Research in Oncology, 2023. Verfasst von Salma AL-Mohammed und 5 weiteren Autor:innen.
Abstract (Originalsprache)
Objectives
The Primary objective of this study is to assess the outcome of Allogenic Bone Marrow Transplantation for B- Thalassemia Major (B-TM) Patients at KFSHD, also to compare our local results with international outcomes, and to identify the complications of this modality of treatment in our cohort.
Design
This is a retrospective descriptive study. It includes all patients’ less16 year transfusion-dependent, b-TM patients who underwent matched-related donor (MRD) allogeneic stem cell transplantation at KFSHD, pediatric hematology/ oncology department between January 2013 and December 2020. Total number of cohort is 21 patients.
Methods
After obtaining the IRB approval, all the data and information were retrieved from the patients’ hard and electronic medical records and then computerized using a Microsoft Excel sheet. Computerized data exported to (SPSS) program updated version 24 (IBM Corp., Armonk, NY, USA) which was used for analysis of the data.
Results
The results of the 21 patients with b-TM who underwent MRD allogenic BMT at KFSHD highlighted the role of MRD/BMT as curative therapy of b-TM with no increase in transplantation-related complications when compared with similar results. In our study, SOS rate was found to be 33.3%, GVHD was 23.8% but non-invasive infections were 76.2%, which is high but not influential. The overall survival (OS) was 90.5% and the disease-free survival (DFS) was 95.2%.
Conclusion
Because of the perfect, promising figures of survival for stem cell transplantation in b-thalassemia major (b-TM) patients during the last decades and the noticeable improvement in the quality of their life after that, and since our study showed similar good comparable outcome and survival rates with other international centers, we strongly recommend early transplantation for b-TM if a suitable donor is available in an experienced BMT center. The overall survival (OS) was 90.5% and the disease-free survival (DFS) was 95.2%, which are comparable outcomes with other international similar centers.
Zitieren
APA
AL-Mohammed, S., Omer, H., AL-Horani, S. E., AL-Hawaj, G. A., Khairy, A., & Aldaama, S. (2023). The Outcomes of Allogenic Bone Marrow Transplantation for BThalassemia Major Patients: Single-Centre Experience. International Journal of Research in Oncology. https://doi.org/10.33425/2833-0390.1014
Vancouver
AL-Mohammed S, Omer H, AL-Horani SE, AL-Hawaj GA, Khairy A, Aldaama S. The Outcomes of Allogenic Bone Marrow Transplantation for BThalassemia Major Patients: Single-Centre Experience. International Journal of Research in Oncology. 2023. doi:10.33425/2833-0390.1014
BibTeX
@article{ALMohammed2023,
author = {AL-Mohammed, Salma and Omer, Hala and AL-Horani, Saif EL-Deen and AL-Hawaj, Ghufran Ali and Khairy, Ashraf and Aldaama, Saad},
title = {The Outcomes of Allogenic Bone Marrow Transplantation for BThalassemia Major Patients: Single-Centre Experience},
journal = {International Journal of Research in Oncology},
year = {2023},
doi = {10.33425/2833-0390.1014}
}
EUVIMED